181 related articles for article (PubMed ID: 37219076)
21. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
[TBL] [Abstract][Full Text] [Related]
22. [Cutaneous localization of T-cell prolymphocytic leukemia].
Thomas A; Dompmartin A; Troussard X; Moreau A; Manard C; Leroy D
Ann Dermatol Venereol; 1995; 122(8):526-9. PubMed ID: 8572493
[TBL] [Abstract][Full Text] [Related]
23. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
24. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
25. Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy.
Sakhdari A; Tang G; Ginsberg LE; Hirsch-Ginsberg CF; Bueso-Ramos CE; Medeiros LJ; Miranda RN
Case Rep Pathol; 2019; 2019():4915086. PubMed ID: 30941227
[TBL] [Abstract][Full Text] [Related]
26. A pediatric case of T-cell prolymphocytic leukemia.
Mitton B; Coutre S; Willert J; Schlis K; Porteus M; Kharbanda S; Agarwal-Hashmi R
Pediatr Blood Cancer; 2015 Jun; 62(6):1061-2. PubMed ID: 25417638
[TBL] [Abstract][Full Text] [Related]
27. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis.
Ingrasci G; Diaz-Perez J; Verne S; Romanelli P; Yosipovitch G
Am J Dermatopathol; 2021 Jul; 43(7):521-524. PubMed ID: 33606377
[TBL] [Abstract][Full Text] [Related]
29. [Cerebriform variant type of T cell prolymphocytic leukemia: Report of one case].
Peña C; Valladares X; Soto C; Encina A; Marinov N; Undurraga MS; Cabrera ME
Rev Med Chil; 2016 Jan; 144(1):124-8. PubMed ID: 26998991
[TBL] [Abstract][Full Text] [Related]
30. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous infiltration in T-cell prolymphocytic leukaemia.
Mallett RB; Matutes E; Catovsky D; Maclennan K; Mortimer PS; Holden CA
Br J Dermatol; 1995 Feb; 132(2):263-6. PubMed ID: 7888364
[TBL] [Abstract][Full Text] [Related]
32. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
33. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous involvement as the first manifestation in a case of T-cell prolymphocytic leukaemia.
Serra A; Estrach MT; Martí R; Villamor N; Rafel M; Montserrat E
Acta Derm Venereol; 1998 May; 78(3):198-200. PubMed ID: 9602226
[TBL] [Abstract][Full Text] [Related]
35. CD30-positive EBV-associated diffuse large B-cell lymphoma occurring after immunosuppressive therapy for T-cell prolymphocytic leukemia.
Alduaij A; Treaba DO; Winer ES
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):64-7. PubMed ID: 21454193
[TBL] [Abstract][Full Text] [Related]
36. T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient.
Salim O; Salim DK; Berker S; Undar L
J Cancer Res Ther; 2015; 11(4):950-3. PubMed ID: 26881553
[TBL] [Abstract][Full Text] [Related]
37. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
38. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
Garand R; Goasguen J; Brizard A; Buisine J; Charpentier A; Claisse JF; Duchayne E; Lagrange M; Segonds C; Troussard X; Flandrin G
Br J Haematol; 1998 Nov; 103(2):488-94. PubMed ID: 9827924
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
40. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
